October 24, 2008
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Origenis expands drug research pact with Alcon
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
MUNICH, Germany — Origenis has widened its drug discovery research agreement with Alcon Research Ltd. to create and develop small molecules for ophthalmic treatment, the company announced in a press release.
The agreement is designed to merge Origenis' small molecule discovery platform, MOREsystem, and Alcon's ophthalmic drug development infrastructure to develop molecules aimed at specific ophthalmic targets, according to the release.
Under terms of the alliance, Alcon will retain the rights to any products developed for ophthalmic and nasal applications; Origenis will hold rights to all other uses of drug candidates developed through the alliance. Alcon will pay Origenis a series of payments and sales royalties.